Abstract
Menopausal transition results from declining ovarian function and leads to dramatic decreases in estrogens, which turns into a number of disturbances. Because climacteric symptoms result from a decrease in estrogens, it naturally follows that replacing estrogens with hormone replacement therapy (HRT) is effective against menopausal symptoms. HRT is the most effective treatment to reduce the frequency and intensity of hot flushes and vaginal atrophy and positively affects bone loss and risk of fractures. Doubts still linger on the impact of HRT on cardiovascular disease, breast cancer, cognitive impairment, and dementia. Recent data supports the initiation of HRT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. Evidence of a direct link between time since menopause and initiation of HRT has also emerged, which may affect the impact on cardiovascular disease and brain deterioration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pines A, Sturdee DW, MacLennan AH (2012) Quality of life and the role of the menopausal hormone therapy. Climacteric 15:213–216
Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flushes: scientific review. JAMA 291:1610–1620
Vernet Mdel M, Checa MA, Macia F, Casamitjana M, Carreras R (2006) Influence of hormone replacement therapy on the accuracy of screening mammography. Breast J 12:154–158
Barnabei VM, Cochrane BB, Aragaki AK, Women’s Health Initiative Investigators et al (2005) Menopausal symptoms and treatment related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 105:1063–1073
National Institutes of Health; State-of-the-Science Panel (2005) National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 142:1003–1013
Schiff I, Tulchinsky D, Cramer D, Ryan KJ (1980) Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 244:1443–1445
Suckling J, Kennedy R, Lethaby A, Roberts H (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Sys Rev (4):CD001500
Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA (2009) Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev (4):CD001405
Townsend MK, Curhan GC, Resnick NM, Grodstein F (2010) The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol 202:378.e1–378.e7
Hendrix SL, Cochrane BB, Nygaard IE et al (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948
Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T, HERS Research Group (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Study. Obstet Gynecol 97:116–120
Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756
Eriksen BC (1999) A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 80:1072–1079
Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR (1998) Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239–2243
Cauley JA, Robbins J, Chen Z, Women’s Health Investigators et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative Randomized Trial. JAMA 290:1729–1738
Jackson RD, LaCroix AZ, Gass M, Women’s Health Investigators et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2676
Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s health initiative randomized trials. JAMA 310:1353–1368
Heiss G, Wallace R, Anderson GL, WHI Investigators et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045
LaCroix AZ, Chlebowski RT, Manson JE, WHI Investigators et al (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314
Zandi PP, Carlson MC, Plassman BL et al (2002) Hormonal replacement therapy and incidence of Alzheimer Disease in Older Women. JAMA 288:2123–2129
Yaffe K, Sawaya G, Lieberburg I, Grady D (1998) Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279:688–695
Kang JH, Weuve J, Grodstein F (2004) Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 63:101–107
Resnick SM, Maki PM, Rapp SR et al (2006) Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 91:1802–1810
Greendale GA, Huang MH, Wight RG et al (2009) Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 72:1850–1857
Simoncini T, Genazzani AR (2007) Timing is everything. Gynecol Endocrinol 23:1–4
Herrington DM, Reboussin DM, Brosnihan KB et al (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522–529
Prest SJ, May FE, Westley BR (2002) The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 16:592–594
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059
Chen WY, Manson JE, Hankinson SE et al (2006) Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166:1027–1032
Pluchino N, Simoncini T, Genazzani AR Ovarian function and menopause. Chapter 99, pp 1199–1210
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454
Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7:R535–R540
Durna E, Wren B, Heller G, Leader L, Sjoblom P, Eden J (2002) Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 177:347–351
Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH (2003) Estrogen replacement therapy in breast cancer survivors: a matched controlled series. Menopause 10:277–285
Beckmann MW, Jap D, Djahansouzi S et al (2001) Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 60:199–206
Marttunen M, Hietanen P, Pyrhonen S, Tiitinen A, Ylikorkala O (2001) A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. Maturitas 39:217–225
DiSaia P, Brewster W, Ziogas A, Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 23:541–545
Ursic-Vrscaj M, Bebar S (1999) A case–control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 25:146–151
Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P (2011) Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients–data from LIBERATE trial. Maturitas 70(4):365–372
Gambacciani M, Monteleone P, Sacco A, Genazzani AR (2003) Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 17:139–147
Weiderpass E, Adami HO, Baron JA et al (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91:1131–1137
Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106:574–582
Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J (2007) Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev 24;(1):CD001216
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Bernacchi, G., Spina, S., Cecchi, E., Genazzani, A.R., Simoncini, T. (2015). Menopause and HRT: Doubts and Certainties. In: Fauser, B.C.J.M., Genazzani, A.R. (eds) Frontiers in Gynecological Endocrinology. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-09662-9_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-09662-9_18
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09661-2
Online ISBN: 978-3-319-09662-9
eBook Packages: MedicineMedicine (R0)